

Δ^9 -tetrahydrocannabinol inhibits epithelial-mesenchymal transition and metastasis by targeting matrix metalloproteinase-9 in endometrial cancer

YINGZHI ZHANG^{1,2}, WEI ZHENG¹, KEWEI SHEN² and WEIWEI SHEN²

¹Department of Gynecology, The Second Affiliated Hospital of Zhejiang University School of Medicine;

²Department of Gynecology, The Affiliated Hospital of School of Medicine of Ningbo University, Hangzhou, Zhejiang 310058, P.R. China

Received October 16, 2017; Accepted February 28, 2018

DOI: 10.3892/ol.2018.8407

Abstract. Limited therapeutic interventions are clinically available for treating aggressive endometrial cancer (EC). Therefore, effective therapies are urgently required. Therefore, the present study investigated the role of Δ^9 -tetrahydrocannabinol (THC), which is reported to impact proliferative and migratory activities during impairment of cancer progression. In the present study, cell migration in response to THC was measured using transwell assays. Using western blot analysis, the levels of cannabinoid receptors in EC tissues were detected and pathways leading to the inhibition of cell migration by THC on human EC cells were determined. Results suggested that cannabinoid receptors were highly expressed in EC tissues. Furthermore, THC inhibited EC cell viability and motility by inhibiting epithelial-mesenchymal transition (EMT) and downregulating matrix metalloproteinase-9 (MMP-9) gene expression in aggressive human EC cells. The results have the potential to promote the development of novel compounds for the treatment of EC metastasis. The present findings suggest that THC may inhibit human EC cell migration through regulating EMT and MMP-9 pathways.

Introduction

As the most prevalent gynecologic malignancy, endometrial cancer (EC) is increasingly populated in the world, especially in the United States (1). According to associated

report, EC can be classified into type I and II tumors in general (2). Moreover, with regard to different disease stages, the therapies of EC are various. At the early stage of most EC patients, only surgery is considered as the effective treatment method (3). As a result of tumor recurrence and metastasis, even under surgical resection plus systemic chemotherapy, the prognosis is still at a poor level for the newly diagnosed EC patients. Therefore, it is significant to explore novel therapies and elucidate the underlying molecular mechanism.

Cannabis sativa plant has been exploited to provide recreational and medicinal usage from the very beginning (4). It consists of over 60 kinds of cannabinoids, who exert a wide spectrum of psycho-active and immuno-active effects. Δ^9 -tetrahydrocannabinol (THC) is known to be the most active constituent of cannabinoids (5). Cannabinoids exert most of their actions by binding to specific G_{ai} protein-coupled receptors, CB₁ receptor (central-type receptor) (6) and CB₂ receptor (peripheral-type receptor) (7), respectively. CB₁ receptor is widely distributed in the central nervous system where they mediate psychoactive effects although it has also been detected in reproductive organs such as uterus and testis (8). CB₂ receptor mainly subjects to specific constituent of the immune system (9).

It is well-known that cannabinoids can act as anti-inflammatory agents and suppress the antitumor immune response. Accordingly, THC has been employed in the field of cancer research recently. Several preclinical studies suggest THC shows anti-cancer performance *in vitro* against breast cancer, lung carcinoma, skin carcinoma, pancreatic cancer and prostate carcinoma (10), while researches seldom relate to EC.

In the present study, we analyze the expression of CB₁ and CB₂ receptors in human EC patient samples over their normal counterparts. We further analyze the biological consequences of THC on aggressive human EC cell lines *in vitro*. Moreover, we also determine the mechanisms of THC that regulate tumor growth and migration of EC. These results shed light on the mechanisms and pathways by which EC occurs and develops, providing evidence that THC prevented EC growth and metastasis through inhibiting epithelial-mesenchymal

Correspondence to: Dr Wei Zheng, Department of Gynecology, The Second Affiliated Hospital of Zhejiang University School of Medicine, 1511, JiangHong Road, Hangzhou, Zhejiang 310058, P.R. China

E-mail: micheal_zheng2017@126.com

Key words: endometrial cancer, Δ^9 -tetrahydrocannabinol, cell migration, epithelial-mesenchymal transition, matrix metalloproteinase-9

transition (EMT) and matrix metalloproteinase-9 (MMP-9) signaling pathway.

Materials and methods

Patients and samples collection. Tissue samples were obtained from 6 Chinese patients who underwent surgical resection for primary EC and para-tumor normal endometrial tissues at The Second Affiliated Hospital of Zhejiang University (Hangzhou, China) between 2014 and 2016. None of the patients had received preoperative treatments such as irradiation or chemotherapy. Written informed consent was obtained from all patients and the study was approved by The Second Affiliated Hospital of Zhejiang University ethics committee. Small pieces (~0.5 cm³) were cut and washed briefly in sterile PBS to remove blood contamination. All the samples were frozen within 20 min of delivery and stored in liquid nitrogen for western blotting and quantitative PCR analysis. The clinical pathological data of all patients are summarized in Table I.

Drugs. Δ⁹-tetrahydrocannabinol (THC, 10 mg/ml in ethanol) was purchased from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany) and store at -20°C.

RNA isolation and RT-qPCR. Briefly, total cellular RNA was extracted using TRIzol® (Thermo Fisher Scientific, Inc., Waltham, MA, USA) following the supplier's instructions. cDNA was generated using 1 mg total RNA and a QuantiTect Reverse Transcription kit (Qiagen, Berlin, Germany). qPCR was performed using SYBR-Green (Bio-Rad Laboratories, Inc., Hercules, CA, USA) methods. The primer sequences for qPCR analysis are shown in Table II.

Western blot analysis. For analysis of CB₁R, CB₂R, E-cadherin, N-cadherin, Vimentin (VIM), MMP-2, MMP-9 expressions, tissues and cells were lysed in RIPA Lysis buffer, then homogenized by vigorous mixing for 30 min on ice, and centrifuged at 12,000 × g for 30 min. Total protein concentration was measured using the bicinchoninic acid assay (Pierce; Thermo Fisher Scientific, Inc., Bonn, Germany). Proteins were separated on a 10% sodium dodecyl sulfate polyacrylamide gel. Following transfer to PVDF membrane and blocking with 5% non-fat milk powder, blots were probed with specific antibodies CB₁R (1:1,000; Abcam, Cambridge, UK), CB₂R (1:1,000; Abcam), E-cadherin (1:1,000; Cell Signaling Technology, Inc., Danvers, MA, USA), N-cadherin (1:1,000; Cell Signaling Technology, Inc.), VIM (1:1,000; Cell Signaling Technology, Inc.), MMP-2 (1:1,000; Abcam), MMP-9 (1:1,000; Abcam) and GAPDH (1:5,000; Abcam) at 4°C overnight. Subsequently, membranes were washed and incubated with anti-rabbit IgG (1:5,000; Cell Signaling Technology, Inc.) or anti-mouse IgG (1:5,000; Cell Signaling Technology, Inc.). Ultimately, proteins were visualized using the enhanced chemiluminescence reagents (Thermo Fisher Scientific, Inc.), and the relative expression of CB₁R and CB₂R, protein levels were analyzed by densitometry using the Image-J imaging analysis software (National Institutes of Health, Bethesda, MD, USA).

ELISA. MMP-9 level was measured in supernatants from cells treated with for 24 h. Protein levels in the supernatants

Table I. Clinical characteristics of all patients.

Demographics	N=6
Age (mean ± SD)	59.2±8.23
BMI (mean ± SD)	30.62±5.82
FIGO	
IA	3
IB	3

Data are shown as mean ± standard error of the mean. BMI, body mass index; FIGO, International Federation of Gynecology and Obstetrics.

Table II. Gene primers for reverse transcription-quantitative polymerase chain reaction analysis.

Gene	Primer
CB ₁ R	F: 5'-TTACAACAAGTCTCTCTCGTCCT-3' R: 5'-GGCTGCCGATGAAGTGGTA-3'
CB ₂ R	F: 5'-GGGTGACAGAGATAGCCAATGG-3' R: 5'-TGAACAGGTATGAGGGCTTCC-3'
MMP-9	F: 5'-GGGACGCAGACATCGTCATC-3' R: 5'-TCGTCATCGTCGAAATGGGC-3'
E-cadherin	F: 5'-AAAGGCCCATTTTCCTAAAAACCT-3' R: 5'-TGC GTTCTCTATCCAGAGGCT-3'
N-cadherin	F: 5'-TCAGGCGTCTGTAGAGGCTT-3' R: 5'-ATGCACATCCTTCGATAAGACTG-3'
Vimentin	F: 5'-TCCACACGCACCTACAGTCT-3' R: 5'-CCGAGGACCGGGTACATA-3'
β-actin	F: 5'-CCACACCCGCCACCAAGTTCG-3' R: 5'-TACAGCCCCGGGAGCATCGT-3'

Data are shown as mean ± standard error. F, forward; R, reverse.

were assayed using a MMP-9 ELISA kit (R&D Systems, Inc., Minneapolis, MN, USA) following the manufacturer's instruction. Optical density was measured at 450 nm. MMP-9 concentration was calculated by comparing the data to the known standards for MMP-9 proteins.

Cell culture. The EC cell lines HEC-1B, and An3ca were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). All cells were maintained in Dulbecco's modified Eagle's medium (DMEM)-F12 (Gibco; Thermo Fisher Scientific, Inc., Auckland, New Zealand) with 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.) at 37°C in a humidified atmosphere with 5% CO₂.

Cell proliferation assay. Cells were seeded in 96-well plates (2,000 cells/well) in 100 μl of DMEM-F12 medium. Then the medium was changed to one that contained different dose of 0.1-20 μM THC for 24 h, and 20 μl MTS reagent (Promega Corporation, Madison, WI, USA) was added to each well




Figure 1. Expression of CB₁R, CB₂R and EMT marker in EC tissues and paired adjacent normal tissues. (A) Relative CB₁R and CB₂R mRNA expression in EC tissues and paired adjacent normal tissues (n=6, Paired Student's t-test, *P<0.05, **P<0.01 vs. normal). (B) Protein expression levels of CB₁R, CB₂R and VIM in EC tissues and paired adjacent normal tissues as determined by western blot analysis; GAPDH was included as an internal control (n=6, Paired Student's t-test, **P<0.01). (C) Expression correlations between CB₁R or CB₂R and VIM, performed using the Spearman's correlation coefficient test. VIM, vimentin; EMT, epithelial-mesenchymal transition; EC, endometrial cancer.

before incubation at 37°C for 2 h. The absorbance at 450 nm was measured using a SpectraMax 190 microplate reader (Bio-Rad Laboratories, Inc.).

Cell migration assay. Cells were suspended in serum-free DMEM-F12 medium and plated at a density of 5×10^4 cells/well in transwell chambers equipped with 8.0 μ m pore polycarbonate membranes (Corning Incorporated, Corning, NY, USA). Complete medium (800 μ l) was added to the lower chamber. After incubation for 16 h, fluorescent stain (calcein-AM) was added to each chamber and incubated for 30 min. Then, the cells that migrated to the basal side of the membrane were counted at 100x magnification by fluorescence analysis (Nikon Corporation, Tokyo, Japan).

Cell infection. Oligonucleotides for human MMP-9, CB₁R, CB₂R siRNA kit were purchased from GenePharma (Shanghai, China). The kit contains three predesigned duplexes targeting a specific MMP-9 gene. Cells were transfected with MMP-9, CB₁R, CB₂R siRNA or NC using the opti-MEM plus X-treme GENE siRNA transfection reagent (Roche, Mannheim, Germany) according to the instruction. Stably infected cells were selected and processed for further analysis by western blotting. After 48 h of post-transfection, western blot analyses were further performed. For gene overexpression, the recombinant lentiviruses carrying MMP-9 or control were obtained as gifts from colleague and used according to the manufacturer's protocol. Briefly, HEC-1B cells were seeded at 2×10^5 cells/well in a 6-well plate. After adherent cells reached




Figure 2. THC inhibits the proliferation and migration of EC cells. (A) An MTT assay was conducted at different doses of THC to quantify the cell viability of the HEC-1B and An3ca cells for 24 h. (one-way ANOVA and Dunett's post-hot tests, * $P < 0.05$, ** $P < 0.01$ vs. CTL). (B) Transwell migration assays of the HEC-1B cells incubated with THC of 20 μM ; (C) Transwell migration assays of the An3ca cells incubated with THC of 20 μM . Representative images were obtained at x100 magnification, scale bar: 10 μm . The graph shows the relative cell number fold of the vehicle control. (Student's t-test, ** $P < 0.01$, *** $P < 0.001$ vs. CTL). THC, Δ^9 -tetrahydrocannabinol.

~40% confluence, they were infected with an LV-MMP-9 or a control supplemented with 8 $\mu\text{g/ml}$ polybrene (Sigma-Aldrich; Merck KGaA). Treated cells were selected with puromycin to generate puromycin-resistant clones, which were assayed by qPCR and western blotting.

Statistical analysis. All data were expressed as the mean $\pm$ the standard error (SEM) and analyzed using the SPSS 19.0 statistical analysis software (SPSS, Inc., Chicago, IL, USA). Statistical significance was determined using an unpaired Student's t-test and one-way ANOVA followed by Dunett's post-hoc test. $P < 0.05$ was considered to indicate a statistically significant difference.

Results

The cannabinoid receptors are highly expressed in EC tissues. Cannabinoid receptors are overexpressed in different cancers, including skin, breast and lung cancers (11-13). Nevertheless, so far as we are concerned that none work has been indicated to present the expression of cannabinoid receptors in EC. Therefore, we first investigated CB₁R and CB₂R expressions in normal endometrium (6 samples) and paired adjacent normal tissues (6 samples) using PCR and western

blot. These data indicated both CB₁R and CB₂R were overexpressed in EC tissues compared with the normal endometrium (Fig. 1A and B). Moreover, the expressions of CB₁R and CB₂R were positively correlated with VIM, the marker of mesenchymal cells (Fig. 1A and C).

THC regulates EC cell proliferation and migration. In the present study, the effect of THC on cell proliferation was analyzed in EC cell lines HEC-1B and An3ca cells. Fig. 2A showed that THC acted as a concentration-dependent inhibitor of cell growth. Tumor growth and metastasis are the leading causes of cancer-related mortality, specifically, tumor cells can migrate from the site of primary tumor and then invade neighboring tissues. To determine the role of THC in EC progression, the transwell assay was designed to test whether the treatment of THC altered the locomotive potential of tumor cells. After 16 h of incubation, THC resulted in a significant decrease in cell migration (Fig. 2B and C). In conclusion, THC obviously suppressed the proliferation and migration capabilities of HEC-1B and An3ca cells.

THC regulates the transition between epithelial and mesenchymal phenotypes in EC cells. Tumor EMT, a key step for tumor progress, is always defined as specific




Figure 3. THC mediates EMT process in EC cells. (A) qPCR and western blot analysis of E-cadherin, N-cadherin and Vimentin levels in HEC-1B cell after the treatment with THC (20 μ M) for 24 h. (B) qPCR and western blot analysis of E-cadherin, N-cadherin and Vimentin levels in An3ca cell after the treatment with THC (20 μ M) for 24 h. The graph shows the relative concentrations of E-cadherin, N-cadherin and Vimentin fold of the vehicle control. (Student's t-test, * P <0.05, ** P <0.01 vs. CTL). THC, Δ 9-tetrahydrocannabinol; EMT, epithelial-mesenchymal transition; EC, endometrial cancer.




Figure 4. THC regulates MMP-9 expression in EC cells. (A) qPCR analysis of MMP-9 mRNA levels in HEC-1B and An3ca cells after the treatment with THC (20 μ M) for 24 h. Relative mRNA expression of MMP-9 fold of the vehicle control (Student's t-test, * P <0.05, *** P <0.001 vs. CTL) was indicated. (B) ELISA analysis of MMP-9 concentrations in HEC-1B and An3ca cell culture after the treatment with THC (20 μ M) for 24 h. The graph shows the MMP-9 concentration fold of the vehicle control. (Student's t-test, * P <0.05 vs. CTL). (C) Western blot analysis of MMP-2 and MMP-9 levels in HEC-1B and An3ca cells after the treatment with THC (20 μ M) for 24 h. The graph shows the protein expression of MMP-9 fold of the vehicle control. (Student's t-test, *** P <0.001 vs. CTL). THC, Δ 9-tetrahydrocannabinol; MMP, matrix metalloproteinase; EC, endometrial cancer.




Figure 5. MMP-9 is involved in THC-impaired EC cell metastasis. (A) qPCR and (B) western blotting results show that the expression of MMP-9 was reduced in HEC-1B and An3ca cells transfected with MMP-9 siRNA. The graph shows the relative expression of MMP-9 fold of the negative control siRNA. (Student's t-test, ***P<0.001 vs. NC). In the presence of siRNA targeting MMP-9, transwell assay was conducted to evaluate (C) HEC-1B and (D) An3ca cell migration after transfection. The graph shows the relative migrated cell number fold of the negative control siRNA, scale bar: 10 μm (Student's t-test, ***P<0.001 vs. NC). (E) qPCR and (F) western blotting results show that the expression of MMP-9 was increased in HEC-1B cells transfected with MMP-9 lentiviruses. The graph shows the relative expression of MMP-9 fold of the negative control. (Student's t-test, ***P<0.001 vs. NC). (G) Transwell assay was conducted to evaluate effect of THC on OV-MMP-9 HEC-1B cell migration. The graph shows the relative migrated cell number fold of the negative control, scale bar: 10 μm (one-way ANOVA and Dunett's post-hoc test, *P<0.05, **P<0.01, ***P<0.001 vs. NC; #P<0.05 vs. THC). (H) Western blot analysis of E-cadherin and Vimentin levels in HEC-1B cells after THC (20 μM) treatment. The graph shows the relative concentrations of E-cadherin and Vimentin fold of the negative control (one-way ANOVA and Dunett's post-hoc test, *P<0.05, **P<0.01, ***P<0.001 vs. NC; #P<0.05 vs. THC). THC, Δ9-tetrahydrocannabinol; MMP, matrix metalloproteinase; EC, endometrial cancer.




Figure 6. Downregulation of CBR inhibits HEC-1B cell migration and MMP-9 expression. (A) Western blotting result show that the expressions of CB₁R and CB₂R were reduced in HEC-1B cells transfected with CB₁R and CB₂R siRNA compared with negative control siRNA, respectively. (B) Western blotting result show that the expression of MMP-9 was decreased in HEC-1B cells transfected with CB₁R and CB₂R siRNA. The graph shows the relative MMP-9 expression fold of the negative control. (one-way ANOVA and Dunett's post-hoc test, ** $P < 0.01$, *** $P < 0.001$ vs. NC). (C) In the presence of siRNA targeting CB₁R and CB₂R, transwell assay was conducted to evaluate HEC-1B cell migration after transfection. The graph shows the relative migrated cell number fold of the negative control siRNA, scale bar: 10 μ m (one-way ANOVA and Dunett's post-hoc test, ** $P < 0.01$ vs. NC). MMP, matrix metalloproteinase

phenotypic and morphological alterations in epithelial cancer cells, causing them to transform into mesenchymal type cells during metastasis in many cancers (14). In tumor EMT, epithelial molecular markers, including E-cadherin, β -catenin are downregulated, whereas the levels of mesenchymal molecular markers, including N-cadherin, VIM are upregulated (15), we also get the similar result that VIM was elevated in EC tissues (Fig. 1B). In our study, the expressions of EMT protein markers were evaluated to explore the potential relationship between THC and EMT. In the THC-treated HEC-1B and An3ca cells, the level of epithelial cell marker (E-cadherin) was increased, while the mesenchymal cell markers (N-cadherin, and VIM) were both decreased, as determined by western blot analysis and qPCR (Fig. 3A and B) assay. This evidence suggested that THC plays crucial roles in tumor EMT.

THC inhibits MMP-9 expression in EC cells. To elucidate the mechanisms by which THC is engaged in the metastasis of EC cells, we detected the level of MMPs after treated with THC. MMPs are functionally related to tissue remodeling processes, where MMP-2 and MMP-9 can be utilized as catalytic in these processes *in vivo*. Recent researches have been tried to demonstrate the molecular basis and pathophysiology of EC, MMP-9 plays important roles in invasion and metastasis by regulating the signaling pathways that control cell growth and invasion (16). In our study, we also observed THC significantly inhibited the secretion of MMP-9 in HEC-1B and An3ca cells by qPCR, western blot and ELISA assay, while the expression of MMP-2 was not significantly altered (Fig. 4A-C). This result supports the hypothesis that THC regulates EMT and the EC cell metastasis is mediated by MMP-9.

MMP-9 signaling pathway is involved in THC-decreased cell migration. To further confirm that THC decreased EC cell mobility through MMP-9 signaling pathway, siRNA was used to silence the MMP-9 expression in HEC-1B and An3ca cells. The presences of HEC-1B and An3ca cells with MMP-9 silencing was verified by qPCR (Fig. 5A) and western blot analyses (Fig. 5B). Furthermore, the transfection with MMP-9 siRNA decreased the migration capacity of HEC-1B and An3ca cells, as shown by the transwell assay (Fig. 5C and D). In addition, the lentivirus of MMP-9 gene overexpression vector and control vector were infected into HEC-1B cells. Stably infected cells were used to perform cell migration assay (Fig. 5E and F). HEC-1B cells overexpress MMP-9 exhibited significantly higher migratory ability than the control group and also slightly reverse the THC-reduced cell migration (Fig. 5G). Furthermore, MMP-9 overexpression in HEC-1B cells can reverse the EMT protein markers which were changed by THC treatment (Fig. 5H). Overall, these data further indicated that MMP-9 mediates THC-reduced EMT and cell mobility in EC cells.

CB₁R and CB₂R knockdown by siRNA inhibit HEC-1B cell migration and MMP-9 expression. Previous studies (17,18) have shown that chronic THC administration causes downregulation of CBRs. Next, siRNA was used to decrease the active level of CB₁R and CB₂R, which may be the result of THC exposure (Fig. 6A). In addition, downregulation of CB₁R and CB₂R attenuated the MMP-9 expression in HEC-1B cell (Fig. 6B) and also inhibited the migration of HEC-1B cells (Fig. 6C). The data potentially revealed that THC signal transfer into cells through CB₁R and CB₂R to develop anti-tumor ability.

Discussion

EC is still a major clinical challenge because of its aggressive metastasis and the limited effective strategies available against metastasis (19). Cannabinoids have been used both *in vivo* preclinical models and in various human cancer cell lines in the past two decades, which significantly contributes to the development of antitumor drugs. Our study first reported that THC plays a functional role in EC metastasis and EMT. Moreover, THC regulates MMP-9 expression in EC cells. Effects of silencing MMP-9 in EC cells are similar to those caused by THC exposure. In conclusion, our data reveal a new target for intervention in EC metastasis and may increase the future treatment options of EC.

In the present study, we first demonstrated that two main cannabinoid receptors, both CB₁ and CB₂ receptors were highly expressed in EC tissues. Previous studies show that cannabinoid receptors are overexpressed in different cancers including lung and breast cancers. It is demonstrated in (20) that the expression of CB₁R is high in the primary tumor of esophageal squamous cell carcinoma and is remarkably related to metastasis to lymph nodes and distant organs. Next, we need to expand the sample size to further analyze the relationship between cannabinoid receptors expression and EC progression.

The important aspects of effective anti-tumor drugs are their ability to inhibit cancer cell proliferation and migration. Through obstructing the cell cycle and inducing apoptotic cell death, THC prevents breast tumor cell growth (21). Thus, we detected and observed that THC significantly inhibited EC cell proliferation and migration. Similar to THC, CBD can impair cell survival *in vitro* in A549 lung cancer cell line and in primary cells from patients with lung cancer. Meanwhile, CBD can result in tumor regression in A549-xenografted nude mice (22). In addition, Chang *et al* show that THC inhibited BeWo (choriocarcinoma cell line) cell migration via STAT3 signaling pathway (18). Notably, the THC anticancer action *in vitro* also implicates the effects observed *in vivo* (23). It is reported by preliminary clinical investigation in 2006 that THC intratumoural injection was effective and safe for the patients with glioblastoma who had previously failed standard therapy (24). The medical and recreational usages of cannabis currently become a controversial topic (25). The usage of cannabis is not allowed in most countries, although different countries have different attitudes for cannabis (26).

We further explored the potential mechanism by which THC regulated EC cell motility. EMT, a phenotypic cellular process, leads to loss of cell-cell adhesion. In tumor EMT, tumor cells surrounding the epithelial cells and matrix lose their polarity and adhesive properties, thereby enhancing the cells' migratory and invasive abilities (27). MMPs are regarded as key proteins in tumor EMT because they are paramount for cancer proliferation and metastasis. In our present study, MMP-9 protein level in EC cells and cell culture was decreased seriously after treatment of THC, while MMP-2 expression was not decreased. Researchers observed a tendency towards the high expression of MMP-9 in the advanced stages of EC (FIGO IIIA-IV) (28). Moreover, the impact of cannabinoids on MMPs was recorded in (29), in which CB₂R agonists decrease MMP-9 expression in activated T cells without affecting MMP-2. More specifically,

cannabidiol has inhibitory effects on tumor cell invasion, which is consequence of the induction of tissue inhibitor of metalloproteinase 1 (TIMP1) and subsequent inhibition on MMP-9 (30). Additionally, we demonstrated that downregulation of MMP-9 can inhibit EC cell motility and MMP-9 overexpression reversed the THC-attenuated cell migration and EMT protein markers. Furthermore, researchers found CB₂R-selective agonists inhibited cell motility in dendritic cells (DCs) microglia (31) by decreasing MMP-9 level. This was also supported by the evident that knockdown of CB₁R and CB₂R can inhibit cell migration via reducing MMP-9 expression. Therefore, we suggested that THC reduced EC cell migration probably through targeting CBRs and suppression of MMP-9 activity.

Surgery is the standard treatment for early-stage EC patients, but patients with lymph node or distant-organ metastases often have poor clinical outcomes. Therefore, identifying novel therapy to prevent EC cell metastatic potential will help to optimize treating strategies. This current study found that cannabinoid receptors were over expressed in EC tissues and the protein levels were positively correlated with EMT markers. Furthermore, THC has been proven to inhibit EC cell motility and EMT through reducing MMP-9, which makes THC become a novel tumor suppressor in EC.

Acknowledgements

Not applicable.

Funding

The present study was supported by the Medical and Health Science and Technology project of Zhejiang Province (grant no. 2014KYB239).

Availability of data and materials

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

WZ designed the experiments and wrote the manuscript. YZ collected the EC tissues and analyzed the data. KS performed the cell function experiments and WS conducted the molecular biological experiments.

Ethics approval and consent to participate

The study was approved by the Ethics Committee of The Second Affiliated Hospital of Zhejiang University. Written informed consent was obtained from all patients.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. *CA Cancer J Clin* 64: 9-29, 2014.
2. Bokhman JV: Two pathogenetic types of endometrial carcinoma. *Gynecol Oncol* 15: 10-17, 1983.
3. Creasman WT, Ali S, Mutch DG, Zaino RJ, Powell MA, Mannel RS, Backes FJ, DiSilvestro PA, Argenta PA, Pearl ML, *et al*: Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocol. *Gynecol Oncol* 145: 519-525, 2017.
4. van Bakel H, Stout JM, Cote AG, Tallon CM, Sharpe AG, Hughes TR and Page JE: The draft genome and transcriptome of *Cannabis sativa*. *Genome Biol* 12: R102, 2011.
5. Deiana S: Medical use of cannabis. *Cannabidiol: A new light for schizophrenia?* *Drug Test Anal* 5: 46-51, 2013.
6. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC and Bonner TI: Structure of a cannabinoid receptor and functional expression of the cloned cDNA. *Nature* 346: 561-564, 1990.
7. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A and Mechoulam R: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. *Science* 258: 1946-1949, 1992.
8. Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, Greasley PJ, Hansen HS, Kunos G, Mackie K, *et al*: International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: Beyond CB₁ and CB₂. *Pharmacol Rev* 62: 588-631, 2010.
9. Mackie K: Distribution of cannabinoid receptors in the central and peripheral nervous system. *Handb Exp Pharmacol*: 299-325, 2005.
10. Velasco G, Sánchez C and Guzmán M: Towards the use of cannabinoids as antitumour agents. *Nat Rev Cancer* 12: 436-444, 2012.
11. Caffarel MM, Sarrió D, Palacios J, Guzmán M and Sánchez C: Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. *Cancer Res* 66: 6615-6621, 2006.
12. Casanova ML, Blázquez C, Martínez-Palacio J, Villanueva C, Fernández-Aceñero MJ, Huffman JW, Jorcano JL and Guzmán M: Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. *J Clin Invest* 111: 43-50, 2003.
13. Preet A, Qamri Z, Nasser MW, Prasad A, Shilo K, Zou X, Groopman JE and Ganju RK: Cannabinoid receptors, CB₁ and CB₂, as novel targets for inhibition of non-small cell lung cancer growth and metastasis. *Cancer Prev Res (Phila)* 4: 65-75, 2011.
14. Jiang R, Zhang C, Liu G, Gu R and Wu H: MicroRNA-126 inhibits proliferation, migration, invasion, and EMT in osteosarcoma by targeting ZEB1. *J Cell Biochem* 118: 3765-3774, 2017.
15. Xie G, Ji A, Yuan Q, Jin Z, Yuan Y, Ren C, Guo Z, Yao Q, Yang K, Lin X and Chen L: Tumour-initiating capacity is independent of epithelial-mesenchymal transition status in breast cancer cell lines. *Br J Cancer* 110: 2514-2523, 2014.
16. Bauvois B: New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: Outside-in signaling and relationship to tumor progression. *Biochim Biophys Acta* 1825: 29-36, 2012.
17. Burston JJ, Wiley JL, Craig AA, Selley DE and Sim-Selley LJ: Regional enhancement of cannabinoid CB₁ receptor desensitization in female adolescent rats following repeated Delta-tetrahydrocannabinol exposure. *Br J Pharmacol* 161: 103-112, 2010.
18. Chang X, Bian Y, He Q, Yao J, Zhu J, Wu J, Wang K and Duan T: Suppression of STAT3 signaling by Δ9-Tetrahydrocannabinol (THC) induces trophoblast dysfunction. *Cell Physiol Biochem* 42: 537-550, 2017.
19. Shao R: Progesterone receptor isoforms A and B: New insights into the mechanism of progesterone resistance for the treatment of endometrial carcinoma. *Ecancermedicalscience* 7: 381, 2013.
20. Hijiya N, Shibata T, Daa T, Hamanaka R, Uchida T, Matsuura K, Tsukamoto Y, Nakada C, Iha H, Inomata M and Moriyama M: Overexpression of cannabinoid receptor 1 in esophageal squamous cell carcinoma is correlated with metastasis to lymph nodes and distant organs, and poor prognosis. *Pathol Int* 67: 83-90, 2017.
21. Caffarel MM, Andradás C, Pérez-Gómez E, Guzmán M and Sánchez C: Cannabinoids: A new hope for breast cancer therapy? *Cancer Treat Rev* 38: 911-918, 2012.
22. Ramer R, Heinemann K, Merkord J, Rohde H, Salamon A, Linnebacher M and Hinz B: COX-2 and PPAR-γ confer cannabidiol-induced apoptosis of human lung cancer cells. *Mol Cancer Ther* 12: 69-82, 2013.
23. Salazar M, Carracedo A, Salanueva IJ, Hernández-Tiedra S, Lorente M, Egia A, Vázquez P, Blázquez C, Torres S, García S, *et al*: Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. *J Clin Invest* 119: 1359-1372, 2009.
24. Guzmán M, Duarte MJ, Blázquez C, Ravina J, Rosa MC, Galve-Roperh I, Sánchez C, Velasco G and González-Feria L: A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. *Br J Cancer* 95: 197-203, 2006.
25. Kramer JL: Medical marijuana for cancer. *CA Cancer J Clin* 65: 109-122, 2015.
26. Wilkie G, Sakr B and Rizack T: Medical marijuana use in oncology: A review. *JAMA Oncol*: Mar 17, 2016 (Epub ahead of print).
27. Araki K, Shimura T, Suzuki H, Tsutsumi S, Wada W, Yajima T, Kobayashi T, Kubo N and Kuwano H: E/N-cadherin switch mediates cancer progression via TGF-β-induced epithelial-to-mesenchymal transition in extrahepatic cholangiocarcinoma. *Br J Cancer* 105: 1885-1893, 2011.
28. Grybos A and Bar J: The relationships between the immun-expression of KAI1, MMP-2, MMP-9 and steroid receptors expression in endometrial cancer. *Folia Histochem Cytobiol* 52: 187-194, 2014.
29. Ghosh S, Preet A, Groopman JE and Ganju RK: Cannabinoid receptor CB₂ modulates the CXCL12/CXCR4-mediated chemotaxis of T lymphocytes. *Mol Immunol* 43: 2169-2179, 2006.
30. McAllister SD, Murase R, Christian RT, Lau D, Zielinski AJ, Allison J, Almanza C, Pakdel A, Lee J, Limbad C, *et al*: Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. *Breast Cancer Res Treat* 129: 37-47, 2011.
31. Adhikary S, Kocieda VP, Yen JH, Tuma RF and Ganea D: Signaling through cannabinoid receptor 2 suppresses murine dendritic cell migration by inhibiting matrix metalloproteinase 9 expression. *Blood* 120: 3741-3749, 2012.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.